The CARMA Technique Study
Launched by PRINCESS ALEXANDRA HOSPITAL, BRISBANE, AUSTRALIA · Oct 18, 2021
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
The CARMA Technique Study is a clinical trial that aims to improve how doctors remove polyps from the colon, which are growths that can sometimes lead to colorectal cancer. The study is testing a new method called the Cap Assisted Resection Margin Assessment (CARMA) technique. This technique helps doctors check that they have completely removed the polyp by using advanced imaging tools during the procedure. The goal is to reduce the chances of polyps growing back after they have been removed, which is a common issue that can lead to further health problems.
To participate in this study, individuals must have colonic polyps and meet certain criteria. For example, participants can have up to two polyps removed, but they should not have small polyps (less than 10mm) that have already been completely removed during a previous procedure. If you join the study, you can expect to undergo a standard procedure to remove the polyp while the doctors use the new CARMA technique to ensure it is done safely and effectively. This trial is open to people aged 18 and older, regardless of gender, and is currently looking for participants. If you have any questions about your eligibility or the study itself, it's a good idea to talk to your doctor.
Gender
ALL
Eligibility criteria
- • Patients with colonic polyps will be considered following below criteria
- Inclusion Criteria:
- • - any polypectomy (though only a maximum of two polyps from one individual participant)
- Exclusion Criteria:
- • polyps less than 10mm which were resected under endoscopic view with a definite \> 1mm clear margin
- • scar site recurrence polyps
- • polyps with endoscopic evidence of invasion
- • pedunculated polyps
- • pseudopolyps
- • participants who will not be available for follow up endoscopy
About Princess Alexandra Hospital, Brisbane, Australia
Princess Alexandra Hospital (PAH) in Brisbane, Australia, is a leading tertiary healthcare facility renowned for its commitment to innovative clinical research and patient care. As a prominent clinical trial sponsor, PAH collaborates with multidisciplinary teams to advance medical knowledge and improve treatment outcomes across various specialties. The hospital is equipped with state-of-the-art facilities and a diverse patient population, enabling researchers to conduct high-quality, ethically sound trials that contribute significantly to the advancement of healthcare both locally and globally. PAH’s dedication to excellence in research is underscored by its adherence to rigorous regulatory standards and a focus on patient safety and wellbeing.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Woolloongabba, Queensland, Australia
Patients applied
Trial Officials
Alexander Huelsen, MD
Principal Investigator
Princess Alexandra Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials